98%
921
2 minutes
20
The degradation of mesoporous silica nanoparticles (MSNs) in the biological milieu due to silica hydrolysis plays a fundamental role for the delivery of encapsulated drugs and therapeutics. However, little is known on the evolution of the pore arrangement in the MSNs in biologically relevant conditions. Small Angle X-ray scattering (SAXS) studies were performed on unmodified and PEGylated MSNs with a MCM-48 pore structure and average sizes of 140 nm, exposed to simulated body fluid solution (SBF) at pH 7.4 for different time intervals from 30 min to 24 h. Experiments were performed with silica concentrations below, at and over 0.14 mg/mL, the saturation concentration of silica in water at physiological temperature. At silica concentrations of 1 mg/mL (oversaturation), unmodified MSNs show variation in interpore distances over 6 h exposure to SBF, remaining constant thereafter. A decrease in radius of gyration is observed over the same time. Mesoporosity and radius of gyration of unmodified MSNs remain then unchanged up to 24 h. PEGylated MSNs at 1 mg/mL concentration show a broader diffraction peak but no change in the position of the peak is observed following 24 h exposure to SBF. PEGylated MSNs at 0.01 mg/mL show no diffraction peaks already after 30 min exposure to SBF, while at 0.14 mg/mL a small diffraction peak is present after 30 min exposure but disappears after 1 h.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.colsurfb.2022.112797 | DOI Listing |
Nanoscale
June 2025
Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada.
Mesoporous silica nanoparticles (MSNs) have garnered significant attention for diverse bioscience applications due to their tunable surface properties and high biocompatibility. Functionalization with hydrophilic polymers like poly(ethylene glycol) (PEG) silane chemistry is commonly employed to reduce non-specific protein adsorption and enhance stability in physiological environments. However, characterizing surface ligands, particularly in aqueous environments, remains a key challenge.
View Article and Find Full Text PDFInt J Biol Macromol
May 2025
Nanomedicine Laboratories, Center for Materials Science, Zewail City of Science and Technology, 6th of October City, 12578 Giza, Egypt. Electronic address:
Lung cancer remains one of the most lethal malignancies globally, underscoring the dire need for effective therapy. Scheduled administration of gemcitabine (GMC) followed by docetaxel (DTX) is clinically employed. Yet, the detrimental systemic toxicity and pharmacokinetic inadequacies such as the short plasma half-life of the former and poor bioavailability of the latter limit their use.
View Article and Find Full Text PDFJ Drug Target
November 2024
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
Overexpression of permeability-glycoprotein (P-gp) transporter leads to multidrug resistance (MDR) through cellular exclusion of chemotherapeutics. Co-administration of P-gp inhibitors and chemotherapeutics is a promising approach for improving the efficacy of therapy. Nevertheless, problems in pharmacokinetics, toxicity and solubility limit the application of P-gp inhibitors.
View Article and Find Full Text PDFACS Nano
May 2024
Research Center for Applied Sciences, Academia Sinica, Taipei 11529, Taiwan.
Mesoporous silica nanoparticles (MSNs) represent a promising avenue for targeted brain tumor therapy. However, the blood-brain barrier (BBB) often presents a formidable obstacle to efficient drug delivery. This study introduces a ligand-free PEGylated MSN variant (RMSN-PEG-TA) with a 25 nm size and a slight positive charge, which exhibits superior BBB penetration.
View Article and Find Full Text PDFAdv Healthc Mater
September 2024
School of Pharmaceutical Sciences, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiang'an South Road, Xiamen, Fujian, 361102, China.
Innovative silica nanomaterials have made the significant advancements in curative therapy against cancers with multidrug resistance (MDR). The study on different-nanostructured mesoporous silica nanoparticles (MSNs) with discrepant pore sizes affecting biomacromolecules in resisting cancer MDR hasn't been reported yet. In this study, a systematic comparison of 6 nm-pore sized hollow-structured MSNs (HMSNs) and 10 nm-pore sized dendrimers-structured MSNs (LMSNs) for delivering Bcl-2-functional converting peptide (N9) or doxorubicin (DOX) to overcome cancer MDR is comprehensively carried out both in in vitro and in vivo resistant tumor models.
View Article and Find Full Text PDF